NCNA NuCana plc Sponsored ADR

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar

NuCana Expands its Board of Directors with the Appointment of Bali Muralidhar
EN
13/10/2020

Underlying

NCNANuCana plc Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NuCana plc Sponsored ADR

 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Reports First Quarter 2025 Financial Results and Provides Busin...

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Anticipated Cash Runway Extended into Q4 2026 to Support Key Value-Driving Milestones and Complete the Expansion Study of NUC-7738 EDINBURGH, United Kingdom, Jun...

June 2, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Prices $7 Million Registered Direct Offering

NuCana Prices $7 Million Registered Direct Offering EDINBURGH, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise price of $0.8068 per share and (ii) a Series...

May 6, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and ...

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financi...

March 20, 2025 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Reports Third Quarter 2024 Financial Results and Provides Busin...

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024 Announced Promising Phase 1b/2 Data on NUC-3373 in Combination with Pembrolizumab or Docetaxel Anticipated Cash Runway into Q2 2025 EDINBURGH, United Kingdom, Nov. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2024 and provided an update on its clinical development program with its tw...

November 25, 2024 1 EN
 PRESS RELEASE
Free
NCNA NuCana plc Spon...

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Stud...

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Pembrolizumab One Patient Achieved a 100% Reduction in their Target Lesion Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plu...

November 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch